These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 28043150

  • 1. Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
    Burianova I, Kuzelova K, Mitrovsky O, Spicka I, Stockbauer P, Zackova M.
    Neoplasma; 2017; 64(2):228-237. PubMed ID: 28043150
    [Abstract] [Full Text] [Related]

  • 2. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D.
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
    Qiu X, Rong X, Yang J, Lu Y.
    BMC Ophthalmol; 2019 Feb 04; 19(1):42. PubMed ID: 30717701
    [Abstract] [Full Text] [Related]

  • 4. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K, Fang XS, Feng LL, Jiang YJ, Zhou XX, Liu X, Li PP, Chen N, Ding M, Wang N, Zhang J, Wang X.
    Cancer Lett; 2015 Apr 10; 359(2):250-8. PubMed ID: 25636517
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.
    Elknerova K, Myslivcova D, Lacinova Z, Marinov I, Uherkova L, Stöckbauer P.
    Neoplasma; 2011 Apr 10; 58(1):35-44. PubMed ID: 21067264
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K, Stepulak A.
    PLoS One; 2015 Apr 10; 10(11):e0143013. PubMed ID: 26580554
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
    Jarząb A, Łuszczki JJ, Guz M, Gumbarewicz E, Polberg K, Stepulak A.
    Anticancer Res; 2017 Mar 10; 37(3):1067-1074. PubMed ID: 28314266
    [Abstract] [Full Text] [Related]

  • 10. HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury.
    Ruess DA, Probst M, Marjanovic G, Wittel UA, Hopt UT, Keck T, Bausch D.
    PLoS One; 2016 Mar 10; 11(8):e0161233. PubMed ID: 27513861
    [Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
    Carbajo-García MC, García-Alcázar Z, Corachán A, Monleón J, Trelis A, Faus A, Pellicer A, Ferrero H.
    Fertil Steril; 2022 Feb 10; 117(2):433-443. PubMed ID: 34809976
    [Abstract] [Full Text] [Related]

  • 12. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
    Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA.
    Apoptosis; 2004 Sep 10; 9(5):573-82. PubMed ID: 15314285
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
    Rao M, Valentini D, Zumla A, Maeurer M.
    Int J Infect Dis; 2018 Apr 10; 69():78-84. PubMed ID: 29501835
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
    Imesch P, Dedes KJ, Furlato M, Fink D, Fedier A.
    Int J Oncol; 2009 Sep 10; 35(3):631-40. PubMed ID: 19639184
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS.
    Apoptosis; 2010 Oct 10; 15(10):1256-69. PubMed ID: 20582477
    [Abstract] [Full Text] [Related]

  • 19. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
    Duncan HF, Smith AJ, Fleming GJ, Partridge NC, Shimizu E, Moran GP, Cooper PR.
    J Cell Physiol; 2016 Apr 10; 231(4):798-816. PubMed ID: 26264761
    [Abstract] [Full Text] [Related]

  • 20. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP.
    Exp Hematol; 2005 Jan 10; 33(1):53-61. PubMed ID: 15661398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.